Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer
| العنوان: | Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer |
|---|---|
| المؤلفون: | James Meehan, Mark Gray, Carlos Martínez-Pérez, Charlene Kay, Lisa Y. Pang, Jennifer A. Fraser, Amy V. Poole, Ian H. Kunkler, Simon P. Langdon, David Argyle, Arran K. Turnbull |
| المصدر: | Frontiers in Oncology Meehan, J, Gray, M, Martinez-Perez, C, Kay, C, Pang, L, Fraser, J, Poole, A, Kunkler, I, Langdon, S, Argyle, D & Turnbull, A 2020, ' Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer ', Frontiers in Oncology . https://doi.org/10.3389/fonc.2020.00628Test Frontiers in Oncology, Vol 10 (2020) |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Biomedical Science Research Group, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Palliative treatment, medicine.medical_treatment, precision medicine, Review, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Circulating tumor cell, breast cancer, molecular signatures of radiosensitivity, Internal medicine, Medicine, Dosing, Radiosensitivity, biomarkers of radiation-induced toxicity, biomarkers of radiosensitivity, business.industry, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Precision medicine, Response to treatment, Radiation therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, biomarkers of radiosensitivity, breast cancer, precision medicine, molecular signatures of radiosensitivity, biomarkers of radiation-induced toxicity, business |
| الوصف: | Radiotherapy remains an important treatment modality in nearly two thirds of all cancers, including the primary curative or palliative treatment of breast cancer. Unfortunately, largely due to tumour heterogeneity, tumour radiotherapy response rates can vary significantly, even between patients diagnosed with the same tumour type. Although in recent years significant technological advances have been made in the way radiation can be precisely delivered to the gross tumour volume, it is proving more difficult to personalise radiotherapy regimens based on tumour biology. Biomarkers that provide prognostic or predictiveinformation regarding a tumour’s intrinsic radiosensitivity or its response to treatment could prove valuable in helping to personalise radiation dosing, enabling clinicians to make decisions between different treatment options whilst avoiding radiationinduced toxicity in patients unlikely to gain therapeutic benefit. Studies have investigated numerous ways in which both patientand tumour radiosensitivities can be assessed. Tumour molecular profiling has been used to develop radiosensitivity gene signatures, while the assessment of specific intracellular or secreted proteins, including circulating tumour cells, exosomes and DNA, has been performed to identify prognostic or predictive biomarkers of radiation response. Finally, the investigation of biomarkers related to radiation-induced toxicity could provide another means by which radiotherapy could become personalised. In this review, we discuss studies that have used these methods to identify or develop prognostic/predictive signatures of radiosensitivity, and how such assays could be used in the future as a means of providing personalised radiotherapy. |
| وصف الملف: | PDF; application/pdf |
| تدمد: | 2234-943X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14be39d014a9464484b62aa543f7a46aTest https://pubmed.ncbi.nlm.nih.gov/32391281Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....14be39d014a9464484b62aa543f7a46a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2234943X |
|---|